Loading...
•
Sep 30, 2023
Abeona Therapeutics Q3 2023 Earnings Report
Abeona Therapeutics reported financial results for the third quarter of 2023 and provided corporate updates.
Key Takeaways
Abeona Therapeutics reported a net loss attributable to common shareholders of $11.8 million for the third quarter of 2023. The company's cash, cash equivalents, restricted cash and short-term investments totaled $54.1 million as of September 30, 2023, which is expected to fund operations into the fourth quarter of 2024. The company completed its first-ever U.S. BLA submission and initiated commercial readiness activities for potential U.S. launch of pz-cel.
Completed Abeona’s first-ever U.S. Biologics License Application (BLA) submission in September 2023.
FDA decision on priority review and acceptance of BLA for pz-cel expected by late-November 2023.
Initiated commercial readiness activities for potential U.S. launch of pz-cel.
Cash, cash equivalents, restricted cash and short-term investments totaled $54.1 million as of September 30, 2023.
Forward Guidance
Abeona estimates that its cash and cash equivalents, restricted cash and short-term investments as of September 30, 2023 are sufficient resources to fund operations into the fourth quarter of 2024.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...